Highlights
About
Multifactorial Treatment of Alzheimer's Disease
Exegiline Pharma is developing a novel multifunctional oral drug, MT-031, for the treatment of dementia and Alzheimer's disease. MT-031's structure combines rivastigmine (Exelon) and rasagiline (Azilect) moieties and has the beneficial properties of both and more. It works as a dual acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor as well a selective irreversible inhibition of MAO-A. MT-031 has a brain-permeable novel multifunctional MAO-AChE/BuChe inhibitor, anti-inflammatory properties, neuroprotective activity, and cognitive- and memory-enhancing activities. The molecule and its indications are protected by US and European patents. The company was established at Youdim Pharmaceuticals, a pharmaceutical company and incubator.
Identity
| Name | Exegiline Pharma |
|---|---|
| Slug | exegiline |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4NukkroLDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | Ha-Tsmikha Street 1, Yokne'am Illit, Israel |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}